Education
About Us
Working with TipRanks
Follow Us
Transmedics Group (TMDX)
:TMDX
TMDX Stock Chart & Stats
$146.31
-$4.08(-5.19%)
At close: 4:00 PM EST
$146.31
-$4.08(-5.19%)
Day’s Range― - ―
52-Week Range$55.00 - $148.59
Previous CloseN/A
Volume1.17M
Average Volume (3M)967.54K
Market Cap
$5.00B
Enterprise Value$4.63B
Total Cash (Recent Filing)$466.17M
Total Debt (Recent Filing)$464.75M
Price to Earnings (P/E)59.1
Beta1.06
Next Earnings
Mar 04, 2026EPS Estimate
0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.66
Shares Outstanding34,174,324
10 Day Avg. Volume875,389
30 Day Avg. Volume967,540
Financial Highlights & Ratios
PEG Ratio-0.24
Price to Book (P/B)9.06
Price to Sales (P/S)4.69
P/FCF Ratio-25.60
Enterprise Value/Market Cap0.93
Enterprise Value/Revenue8.17
Enterprise Value/Gross Profit13.55
Enterprise Value/Ebitda34.97
Forecast
1Y Price Target
$143.67Price Target Upside-1.80% Downside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)2.59
Revenue Forecast (FY)$600.89M
Bulls Say, Bears Say
Bulls Say
Market ExpansionPlans for longer-term growth drivers include expansion into Europe and OCS Kidney.
Operational EfficiencyTMDX's gross margin increased by 290 bps Y/Y while its operating margin increased by 1,260 bps Y/Y due to operating leverage.
Revenue GrowthSales increased roughly 32% year-over-year to $143.8 million, with GAAP EPS well ahead of the Street target.
Bears Say
Competition RiskCompetition remains a potential risk for TMDX.
Revenue ExpectationsTMDX delivered revenue slightly short of consensus, which is expected to drive the stock down.
Seasonality ChallengesA recent decline in organ transplant volumes and a slowdown in TransMedics flight data occurred during the third quarter, likely due to typical seasonality in the transplant industry.
TransMedics Group News
TMDX FAQ
What was Transmedics Group’s price range in the past 12 months?
Transmedics Group lowest stock price was $55.00 and its highest was $148.59 in the past 12 months.
What is Transmedics Group’s market cap?
Transmedics Group’s market cap is $5.00B.
When is Transmedics Group’s upcoming earnings report date?
Transmedics Group’s upcoming earnings report date is Mar 04, 2026 which is in 92 days.
How were Transmedics Group’s earnings last quarter?
Transmedics Group released its earnings results on Oct 29, 2025. The company reported $0.66 earnings per share for the quarter, beating the consensus estimate of $0.361 by $0.299.
Is Transmedics Group overvalued?
According to Wall Street analysts Transmedics Group’s price is currently Overvalued.
Does Transmedics Group pay dividends?
Transmedics Group does not currently pay dividends.
What is Transmedics Group’s EPS estimate?
Transmedics Group’s EPS estimate is 0.38.
How many shares outstanding does Transmedics Group have?
Transmedics Group has 34,174,324 shares outstanding.
What happened to Transmedics Group’s price movement after its last earnings report?
Transmedics Group reported an EPS of $0.66 in its last earnings report, beating expectations of $0.361. Following the earnings report the stock price went up 1.094%.
Which hedge fund is a major shareholder of Transmedics Group?
Currently, no hedge funds are holding shares in TMDX
TransMedics Group Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$143.67 (-1.80% Downside)
$143.67 (-1.80% Downside)
Blogger Sentiment
Bullish
TMDX Sentiment 70%
Sector Average 68%
Sector Average 68%
Hedge Fund Trend
Decreased
By 89.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $564.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▲ 0.1%
Last 30 Days ▼ 1.2%
Last 30 Days ▼ 1.2%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
67.96%
12-Months-Change
Fundamentals
Return on Equity
32.48%
Trailing 12-Months
Asset Growth
20.43%
Trailing 12-Months
Company Description
Transmedics Group
TransMedics Group (TMDX) is a pioneering medical technology company focused on improving organ transplantation outcomes through its innovative Organ Care System (OCS). Operating in the healthcare sector, TMDX specializes in developing and commercializing devices that preserve and transport donated organs, particularly hearts, lungs, and livers, in a viable condition. By utilizing its proprietary OCS technology, the company aims to enhance organ viability and increase the number of successful transplants, thereby addressing the critical shortage of available organs for transplantation.
TMDX Company Deck
TMDX Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented strong year-over-year growth and operational achievements, such as significant revenue growth, improved margins, and international expansion plans. However, there were also challenges including a seasonal slowdown and sequential revenue decline. The overall sentiment is balanced with more highlights than lowlights.View all TMDX earnings summariesTMDX Stock 12 Month Forecast
Average Price Target
$143.67
▼(-1.80% Downside)
Technical Analysis
Ownership Overview
3.57% Insiders
39.79% Mutual Funds
10.20% Other Institutional Investors
23.27% Public Companies and Individual Investors